Pediatric Hematology Oncology Research

This listing changes frequently.  For more information about the trials we have available, please contact us at (551) 996-5627 or via e-mail

Burton Appel, MD

AALL05B1:  Children’s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Burton Appel, MD

AALL08B1:  Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Pro00001704 / III
Burton Appel, MD

AALL0932:  Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

Pro00002711 / III
Burton Appel, MD

AALL1131:  A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

Burton Appel, MD

AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Pro00005494 / III
Burton Appel, MD

AALL1331, Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Burton Appel, MD

AAML08B1:  Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)

Pro00002422 / III
Burton Appel, MD

AAML1031:  A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND# 114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

Pro2016-0141 / III
Burton Appel, MD

AAML1531:  Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Michael B. Harris, MD

ABTR01B1:  A children’s Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors 

Michael B. Harris, MD

ABTR04B1:  Establishing Continuous Cell Lines and xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies

Pro00003215 / II
Derek Hanson, MD

ACCL0922 (SCUSF 0901):  A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Pro00002274 / III
Steven Diamond, MD

ACCL0933:  A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Pro00002442 / III
Steven Diamond, MD

ACCL0934:  A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation(HSCT)

Pro00003134 / III
Burton Appel, MD

ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Carlene Cord, APN

ACCL1034:  Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)

Pro00004268 / III
Jennifer Krajewski, MD

ACCL1131: A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)

Pro00005687 / III
Frances Flug, MD

ACCL1333: A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated Asparaginase

Michael B. Harris, MD

ACCRN07:  Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)

07.02.070C /III
Derek Hanson, MD

ACNS0332:  Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Pro00001761 / III
Derek Hanson, MD

ACNS0831:  Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

Pro00003273 / II
Derek Hanson, MD

ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Pro00004886 / II
Derek Hanson, MD

ACNS1221:  A Phase II Study For The Treatment Of Non-Metastatic Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age

Pro00004706 / II
Burton Appel, MD

ADVL1322: A Phase II Trial of Pazopanib NSC# 737754, IND# 65747 in Children with Refractory Solid Tumors

Michael B. Harris, MD

AEWS07B1:  A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens

Pro00001987 / III
Michael B. Harris, MD

AEWS1031:  A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

Pro00005725 / II
Michael B. Harris, MD

AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Pro00001203 / III
Michael B. Harris, MD

AHEP0731:  Treatment of Children with All Stages of Hepatoblastoma

Pro00005717 / II
Burton Appel, MD

AHOD1221: A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma

Pro00005705 / III
Burton Appel, MD

AHOD1331: A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Michael B. Harris, MD

ALTE03N1:  Key Adverse Events after Childhood Cancer

Michael B. Harris, MD

ALTE05N1:  Umbrella Long-term Follow-up Protocol

Anne Farrar-Anton, PhD

ALTE07C1:  Neuropsychological, Social, Emotional and Behavioral Outcomes in Children With Cancer

Michael B. Harris, MD

ALTE11C1:  Longitudinal Assessment of Ovarian Reserve in Adolescents With Lymphoma

Michael B. Harris, MD

ALTE11C2:  Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy

Burton Appel, MD

ANBL00B1:  Neuroblastoma Classification Biology Studies

Pro00003808 / II
Burton Appel, MD

ANBL1221:  A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

Michael B. Harris, MD

ANBL1232: Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients With Non-High Risk Neuroblastoma

Burton Appel, MD

ANHL04B1:  Rare Cutaneous Non-Hodgkin Lymphoma Registry

Pro00004838 / II
Burton Appel, MD

ANHL12P1:  A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117

Michael B. Harris, MD

AOST06B1:  A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens

Pro2016-0023 / II
Michael B. Harris, MD

AOST1421:  A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma

Burton Appel, MD

APEC14B1:  Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Burton Appel, MD

AREN03B2:  Renal Tumors Classification, Biology, and Banking Study

Pro00005111 / II/III
Burton Appel, MD

ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Burton Appel, MD

D9902:  A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol

Burton Appel, MD

9442:  National Wilms Tumor Late Effects Study

Derek Hanson, MD

AT/RT:  Registry for Central Nervous System Atypical Teratoid/Rhabdoid Tumor

Pro00003350 / IIb
Cindy Steele, MD

MK0517-029 A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Emetogenic Chemotherapy

Steven Diamond, MD

SCNIR:  Severe Chronic Neutropenia International Registry


close (X)